Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

Br J Cancer. 2006 May 22;94(10):1550-2. doi: 10.1038/sj.bjc.6603114.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antineoplastic Agents / administration & dosage*
  • B-Lymphocytes / drug effects
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / secondary
  • Breast Neoplasms / therapy*
  • Female
  • Graft vs Tumor Effect
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Middle Aged
  • Receptor, ErbB-2 / immunology*
  • Receptor, ErbB-2 / metabolism
  • T-Lymphocytes / drug effects
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab